Loading stock data…
Biodesix, Inc. (BDSX)
$22.55-1.26 (-5.29%)
Market ClosedLast close Jun 30
Biodesix, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Biodesix, Inc. in the Healthcare sector is trading at $22.55 with a market capitalization of $167M. Wall Street consensus targets $30.83 (6 analysts), implying a +36.7% move over the next 12 months. The stock is currently near its 52-week high of $24.34, remaining 101.2% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +36.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $25.55M↓ | $28.75M↑ | $21.77M↑ | $20.02M↑ | $17.96M |
| Gross Profit | $21.35M↓ | $23.88M↑ | $17.66M↑ | $15.99M↑ | $14.26M |
| Operating Income | -$6.20M↓ | -$1.97M↑ | -$7.04M↑ | -$9.69M↓ | -$9.06M |
| Net Income | -$7.79M↓ | -$3.98M↑ | -$8.72M↑ | -$11.47M↓ | -$11.10M |
Peer Comparison
JNJUNHPFE
Fundamentals
Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identi...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$166.73M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.42
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-349.95%
Volume
Today's trading volume
113,761
Recent News
Biodesix (BDSX) Stock Gets Fair Value Bump As Analysts Back Growth Path
The latest valuation work on Biodesix nudges the fair value estimate from US$30.50 to US$30.83 per share, a small but telling adjustment that keeps the focus on where the stock might reasonably trade over time. Analysts framing targets in the high US$20s to low US$30s are tying that range to views on Biodesix’s growth profile, margin structure, and the route to adjusted EBITDA breakeven. Read on to see what is driving this evolving narrative and how you can track the key moving...
Biodesix (BDSX) Surges 10.5%: Is This an Indication of Further Gains?
Biodesix (BDSX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Are Medical Stocks Lagging Biodesix (BDSX) This Year?
Here is how Biodesix, Inc. (BDSX) and BillionToOne (BLLN) have performed compared to their sector so far this year.
Zacks Industry Outlook Highlights BrightSpring Health Services, Biodesix and HealthEquity
BTSG, BDSX and HQY are positioned to benefit as digital health, analytics and patient-focused care reshape medical services.
3 Medical Service Industry Stocks Thriving Amid Workforce Challenges
BTSG, BDSX and HQY stand to benefit as digital health, healthcare analytics and nursing care growth offset workforce strains.